6-K filed Aug 12, 2026 at 07:05 ET
Kamada reported record-high Q2 and H1 2026 results with double-digit revenue and profit growth, driven by strong demand for KEDRAB, VARIZIG, and HEPAGAM. The company affirmed its 2026 annual guidance of $200-205M revenue and $50-53M adjusted EBITDA. A new $50M three-year plasma supply agreement was secured, and the company announced the planned transition of its CFO, Chaime Orlev, effective end of 2026. The strong operational performance is partially offset by a slight gross margin decline and the CFO departure introduces a leadership transition risk.